Venkatachalam Sankaran, Krishnan Sowmya Ramaswamy, Pandian Ramesh, Sayed Yasien, Gromiha M Michael
Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, India.
Protein Structure-Function Research Unit, School of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.
Proteins. 2025 Sep;93(9):1426-1435. doi: 10.1002/prot.26817. Epub 2025 Mar 3.
In recent years, Human Immunodeficiency Virus (HIV) remains a significant global health challenge, with millions affected worldwide, particularly in Africa and sub-Saharan regions. Despite advances in antiretroviral therapies, the genetic variability of HIV, including different subtypes and drug-resistant strains, poses persistent obstacles in the development of universally effective treatments. This study focuses on the dynamics of HIV protease, a key enzyme in viral replication and maturation, particularly targeting subtype C and its double insertion (HL) variant L38HL, in the context of interaction with Darunavir (DRV), a second-generation nonpeptidic protease inhibitor approved by the FDA in 2006. Through molecular dynamics simulations, structural analyses, dynamic cross-correlation analyses, and binding energy calculations, we investigated differences in the binding of DRV to WT and L38HL HIV-1 protease. The findings highlight that the double insertion at the hinge induces variation in Φ and Ψ angles, leading to increased residue fluctuations, solvent-accessible surface area (SASA), and radius of gyration (R). This alters the overall structural compactness and the hydrophobic core crucial for drug binding. Subtle structural changes result in the loss of hydrogen bond interactions, reducing the binding energy of L38HL HIV-1 protease subtype C bound to DRV, leading to drug resistance.
近年来,人类免疫缺陷病毒(HIV)仍然是一项重大的全球健康挑战,全球数百万人受到影响,尤其是在非洲和撒哈拉以南地区。尽管抗逆转录病毒疗法取得了进展,但HIV的基因变异性,包括不同的亚型和耐药菌株,在开发普遍有效的治疗方法方面构成了持续的障碍。本研究聚焦于HIV蛋白酶的动力学,这是病毒复制和成熟过程中的一种关键酶,特别针对C亚型及其双插入(HL)变体L38HL,研究其在与2006年美国食品药品监督管理局(FDA)批准的第二代非肽类蛋白酶抑制剂达芦那韦(DRV)相互作用的背景下的情况。通过分子动力学模拟、结构分析、动态交叉相关分析和结合能计算,我们研究了DRV与野生型(WT)和L38HL HIV-1蛋白酶结合的差异。研究结果表明,铰链处的双插入导致了Φ角和Ψ角的变化,从而导致残基波动增加、溶剂可及表面积(SASA)和回转半径(R)增大。这改变了整体结构的紧凑性以及对药物结合至关重要的疏水核心。细微的结构变化导致氢键相互作用丧失,降低了与DRV结合的C亚型L38HL HIV-1蛋白酶的结合能,从而导致耐药性。